[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Hellstern, 2022 - Google Patents

Composition of plasma

Hellstern, 2022

Document ID
2817797292908721373
Author
Hellstern P
Publication year
Publication venue
Rossi's Principles of Transfusion Medicine

External Links

Snippet

This chapter describes the composition of plasma, protein components for treatment with plasma or its derivatives. It also addresses individual factors influencing plasma levels of therapeutic plasma proteins. Age, gender, ABO blood group, acute phase reactions …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis

Similar Documents

Publication Publication Date Title
US6566140B2 (en) Inhibition of coagulation in blood and blood products
Lawson et al. Challenges for providing effective hemostasis in surgery and trauma
Al-Mondhiry et al. Fibrinogen"" New York"--an abnormal fibrinogen associated with thromboembolism: functional evaluation
Bajaj et al. New insights into how blood clots: implications for the use of APTT and PT as coagulation screening tests and in monitoring of anticoagulant therapy
CA2623142C (en) Methods for a global assay of coagulation and fibrinolysis
Demoulin et al. Dual inhibition of factor XIIa and factor XIa as a therapeutic approach for safe thromboprotection
He et al. The clotting trigger is an important determinant for the coagulation pathway in vivo or in vitro—inference from data review
Rick Protein C and Protein S: Vitamin K—Dependent Inhibitors of Blood Coagulation
Wuillemin et al. Inactivation of factor XIa in vivo: studies in chimpanzees and in humans
Hellstern Composition of plasma
Girolami et al. Chromogenic Substrate (S-2238) Prothrombin Assay in Prothrombin Deficiencies and Abnormalities. Lack of Identity with Clotting Assays in Congenital Dysprothrombinemias.
US10006080B2 (en) High-selectivity contact activation inhibitor based on infestin-4
Raivio et al. Monitoring high-dose heparinization during cardiopulmonary bypass–A comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays
Bennett Blood coagulation and coagulation tests
Hiller Basic principles of hemostasis
Asmis Coagulation factor concentrates
Journois et al. Assessment of coagulation factor activation during cardiopulmonary bypass with a new monoclonal antibody
Harbaugh et al. Antithrombin and antithromboplastin activity accompanying IgG myeloma: Report of a case with a severe bleeding tendency
Lewis et al. Coagulopathies
Bick Hereditary plasma protein disorders
Hellstern Composition and mechanisms of blood coagulation and fibrinolysis
Wang et al. Coagulation and Fibrinolysis
Djabbarova et al. MODERN CONCEPTS OF BLOOD COAGULATION MECHANISMS
Girolami et al. Peculiar, poorly known, rare congenital bleeding disorders presenting thrombotic events: an understudied chapter of molecular, blood coagulation defects
Seghatchian Advances in Amidolytic Assay of Factor VIII: Variables Affecting the Rate of Xa Generation